TABLE 2.
MSC therapy in various disease models in animals
| Outcomes | Reference | |
|---|---|---|
| STZ diabetes | Human-MSC grafted kidney and pancreas in STZ NOD.SCID mice ameliorating diabetes and kidney disease | 59 |
| Heart transplantation | Allogenic rat-MSCs injected intravenously migrated to the heart during chronic rejection | 60 |
| Heart transplantation | Allogenic rat-MSCs co-injected with cyclosporine accelerate rejection | 50 |
| Myocardial infarction | Syngeneic rat-MSCs showed an anti-inflammation role in ischemic heart disease | 61 |
| Acute lung injury | Syngeneic intrapulmonary murine-MSCs decrease the severity of endotoxin-induced acute lung injury and improve survival in mice | 62 |
| Chronic lung injury | Syngeneic murine-MSCs protect lung tissue from bleomycin-induced injury with anti-inflammatory effect | 63 |
| Arthritis | Allogenic murine-MSCs reduce joint inflammation and increase Treg generation | 44 |
| Kidney ischemia reperfusion injury | Syngeneic murine-MSCs are helpful in the restoration of tubular epithelial cells with an anti-inflammatory effect | 42 |
| Multiple sclerosis model (EAE) | Syngeneic murine-MSCs are home to inflamed lymphoid tissues reducing disease progression | 43,64 |
| Acute hepatic failure | Human-MSCs protect against hepatocyte death and increase survival in mice after the injections of the hepatotoxin D-galactosamine | 65 |
| GHVD | Allogenic rat-MSCs prevent lethal GVHD | 66 |
| GVHD | Allogenic murine-MSCs did not improve GVHD | 49 |
| BM transplantation | Donor-MSCs increase rejection of allogeneic donor bone marrow cells | 37 |
Italics indicate contrasting reports. MSC were all bone marrow–derived (BM-MSC). EAE, experimental autoimmune encephalomyelitis; STZ, streptozotocin.